Reumacon (CPH82) showed similar x-ray progression and clinical effects as methotrexate in a two year comparative study on patients with early rheumatoid arthritis
(2003) In Scandinavian Journal of Rheumatology 32(2). p.83-88- Abstract
- Objectives. To study x-ray development and clinical effects, tolerability and safety after 2 years treatment of RA patients with Reumacon (CPH82) or methotrexate (MTX). Patients and methods. This study is a 74 week open continuation of a 24 week double blind comparison of 100 patients with early RA (disease duration less than 2 years) treated either with Reumacon or MTX. Results. The mean Larsen scores and the mean number of erosions increased significantly from baseline to 24 weeks and from 24 weeks to endpoint in both groups with no significant difference between them. Both groups had improved significantly in all clinical variables after 24 weeks and this improvement was sustained after two years. Conclusions. Radiological progression... (More)
- Objectives. To study x-ray development and clinical effects, tolerability and safety after 2 years treatment of RA patients with Reumacon (CPH82) or methotrexate (MTX). Patients and methods. This study is a 74 week open continuation of a 24 week double blind comparison of 100 patients with early RA (disease duration less than 2 years) treated either with Reumacon or MTX. Results. The mean Larsen scores and the mean number of erosions increased significantly from baseline to 24 weeks and from 24 weeks to endpoint in both groups with no significant difference between them. Both groups had improved significantly in all clinical variables after 24 weeks and this improvement was sustained after two years. Conclusions. Radiological progression in patients treated with CPH82 was similar to that in patients treated with MTX. The clinical effect of the two drugs was sustained over the two year trial in both treatment groups. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/313234
- author
- Svensson, B and Pettersson, Holger LU
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- randomized trial, Larsen score, progression, x-ray, early rheumatoid arthritis, methotrexate, Reumacon, CPH82
- in
- Scandinavian Journal of Rheumatology
- volume
- 32
- issue
- 2
- pages
- 83 - 88
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000182235800004
- pmid:12737326
- scopus:0037258334
- ISSN
- 1502-7732
- DOI
- 10.1080/03009740310000085
- language
- English
- LU publication?
- yes
- id
- c7bdfed1-c991-4768-bc1e-10d1afafe343 (old id 313234)
- date added to LUP
- 2016-04-01 11:49:11
- date last changed
- 2022-01-26 18:41:21
@article{c7bdfed1-c991-4768-bc1e-10d1afafe343, abstract = {{Objectives. To study x-ray development and clinical effects, tolerability and safety after 2 years treatment of RA patients with Reumacon (CPH82) or methotrexate (MTX). Patients and methods. This study is a 74 week open continuation of a 24 week double blind comparison of 100 patients with early RA (disease duration less than 2 years) treated either with Reumacon or MTX. Results. The mean Larsen scores and the mean number of erosions increased significantly from baseline to 24 weeks and from 24 weeks to endpoint in both groups with no significant difference between them. Both groups had improved significantly in all clinical variables after 24 weeks and this improvement was sustained after two years. Conclusions. Radiological progression in patients treated with CPH82 was similar to that in patients treated with MTX. The clinical effect of the two drugs was sustained over the two year trial in both treatment groups.}}, author = {{Svensson, B and Pettersson, Holger}}, issn = {{1502-7732}}, keywords = {{randomized trial; Larsen score; progression; x-ray; early rheumatoid arthritis; methotrexate; Reumacon; CPH82}}, language = {{eng}}, number = {{2}}, pages = {{83--88}}, publisher = {{Taylor & Francis}}, series = {{Scandinavian Journal of Rheumatology}}, title = {{Reumacon (CPH82) showed similar x-ray progression and clinical effects as methotrexate in a two year comparative study on patients with early rheumatoid arthritis}}, url = {{http://dx.doi.org/10.1080/03009740310000085}}, doi = {{10.1080/03009740310000085}}, volume = {{32}}, year = {{2003}}, }